Showing 5881-5890 of 5956 results for "".
- Novaliq to Present Scientific and Clinical Research During the 2018 ARVO Meeting in Honoluluhttps://modernod.com/news/novaliq-to-present-scientific-and-clinical-research-during-the-2018-arvo-meeting-in-honolulu/2480208/Novaliq announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) meeting in Honolulu, Hawaii (April 29-May 3). The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With th
- Novartis Launches App to Collect Patient Data in Studies for Ophthalmic Diseaseshttps://modernod.com/news/novartis-launches-app-to-collect-patient-data-in-studies-for-ophthalmic-diseases/2480209/Novartis announced the launch of its FocalView app, an ophthalmic digital research platform that aims to allow researchers to track disease progression by collecting real-time, self-reported data directly from consenting patients. By adapting the design of clinical trials to suit the daily routin
- ianTECH’s miLOOP Grabs Two “Best Paper of Session” Wins at the ASCRS-ASOA Annual Meetinghttps://modernod.com/news/iantechs-miloop-grabs-two-best-paper-of-session-wins-at-the-ascrs-asoa-annual-meeting/2480210/Two presentations among the several featuring ianTECH’s novel »miLOOP Device won “Best Paper in Session” awards during the 2018 meeting of the American Society of Catarac
- New CSP Report for the Oculus Pentacamhttps://modernod.com/news/new-csp-report-for-the-oculus-pentacam/2480216/Oculus announced the release of the new CSP Report, allowing the Pentacam to measures sagittal height, a parameter needed for scleral lens fitting. With the upgrade, 250 Scheimpflug images covering a diameter of up to
- Fresenius Kabi Terminates $4.3-Billion Merger Agreement with Akornhttps://modernod.com/news/fresenius-kabi-terminates-4-3-billion-merger-agreement-with-akorn/2480219/Fresenius Kabi announced Sunday that it has decided to abandon its planned takeover of Akorn, citing the latter’s “failure to fulfill
- Lighthouse Guild Offers eLearning Course on Low Vision Assessment for Occupational Therapyhttps://modernod.com/news/lighthouse-guild-offers-elearning-course-on-low-vision-assessment-for-occupational-therapy/2480221/Lighthouse Guild, in partnership with the American Occupational Therapy Association (AOTA), is offering a 2-hour online program designed for occupational therapists in all settings. The course titled “Low Vision Assessment for Occupational Therapy” demonstrates the basic strategies and tools for
- TFOS Recognizes the Bioprotectant Properties of Trehalose, a Component of Thealoz Duo, in the Treatment of Dry Eyehttps://modernod.com/news/tfos-recognizes-the-bioprotectant-properties-of-trehalose-a-component-of-thealoz-duo-in-the-treatment-of-dry-eye/2480223/The TFOS international Dry Eye WorkShop II (TFOS DEWS II), whose report has been published in the July 2017 issue of the Ocular Surface journal, acknowledged that trehalose is an effective ingredient in association with hyaluronic acid for the tre
- Optimo Medical Receives CE Mark for Optimeyes Surgical Planning Toolhttps://modernod.com/news/optimo-medical-receives-ce-mark-for-optimeyes-surgical-planning-tool/2480233/Switzerland-based Optimo Medical AG announced that it has received CE Mark for Optimeyes as a Class 2b medical device. The Optimeyes software predicts in a patient-specific way the influence of physical interventions in the cornea, allowing it to simulate and evaluate treatment results in
- Shire Announces Sale of Oncology Business to Servier for $2.4 Billionhttps://modernod.com/news/shire-announces-sale-of-oncology-business-to-servier-for-2-4-billion/2480237/Shire announced that it has entered into a definitive agreement with privately held French pharmaceutical group Servier S.A.S. to sell its Oncology business for $2.4 billion. “This transaction is a key milestone for Shire, demonstrating the clear value embedded in our portfolio. While the
- Ivantis Announces Results of Comparative MIGS Clinical Trialhttps://modernod.com/news/ivantis-announces-results-of-comparative-migs-clinical-trial/2480238/Ivantis, developer of the Hydrus Microstent, announced the 12-month results of the COMPARE study for minimally invasive glaucoma surgery (MIGS). Results from the study will be presented by David Chang, MD, clinical professor of Ophthalmology at the University of California, San Francisco, during